Novo Nordisk’s Saxenda bags NICE recommendation
Obesity management treatment recommended following confidential discount
Read More
Tag: Saxenda
- Survodutide delivers 16.6% weight loss in major phase 3 obesity trial
- Kahimmune Therapeutics signs collaboration agreement with Gustave Roussy
- BioDuro and CTI Biotechnology form partnership to accelerate preclinical drug development
- Asgard Therapeutics to present new preclinical data on AT‑108 at ASGCT 2026
- Theolytics announces first patient dosed in the Octopod‑IP trial
